# Phenotypic Drug Discovery Agent

**ID:** `biomedical.research_tools.phenotypic_discovery`
**Version:** 1.0.0
**Status:** Production
**Category:** Research Tools / Drug Discovery

---

## Overview

The **Phenotypic Drug Discovery Agent** matches phenotypic profiles from high-content imaging to compound mode-of-action, enabling target-agnostic drug discovery. This approach has led to many first-in-class drug discoveries by identifying compounds with novel mechanisms.

This agent uses AI to link high-content cell imaging with small molecule activity, identifying active compounds, predicting bioactivity, and inferring mechanisms of action.

---

## Key Capabilities

### 1. Profile Matching

| Method | Description | Use Case |
|--------|-------------|----------|
| **Correlation** | Pearson/cosine similarity | Reference matching |
| **Euclidean distance** | Feature space distance | Clustering |
| **Deep metric learning** | Learned embeddings | MOA prediction |
| **Optimal transport** | Distribution matching | Batch correction |

### 2. MOA Prediction

- **Reference-based:** Match to known compound profiles
- **Target-based:** Correlate with genetic perturbations
- **Network-based:** Pathway inference from profiles
- **De novo:** Unsupervised mechanism discovery

### 3. Hit Prioritization

| Criterion | Weight | Rationale |
|-----------|--------|-----------|
| **Activity strength** | 30% | Clear phenotypic effect |
| **Selectivity** | 25% | Specific mechanism |
| **Novelty** | 20% | Distinct from references |
| **Toxicity absence** | 25% | Safety consideration |

### 4. Virtual Screening

- **Profile prediction:** Predict phenotypes from structure
- **QSAR integration:** Structure-activity relationships
- **Transfer learning:** Leverage related assays

---

## Usage

### Example Prompt

```text
Perform phenotypic drug discovery on a kinase inhibitor library.

Input:
- Cell Painting profiles for 500 kinase inhibitors
- Reference profiles for 50 known inhibitors with targets
- DMSO controls

Tasks:
1. Cluster compounds by phenotype
2. Predict kinase targets for novel compounds
3. Identify compounds with novel MOA
4. Prioritize hits for follow-up
```

### Expected Output

```
## Phenotypic Drug Discovery Report: Kinase Inhibitors

### Library Overview
- **Compounds screened:** 500 kinase inhibitors
- **Reference compounds:** 50 (known targets)
- **Active compounds:** 178 (36%)
- **Novel phenotypes:** 23 (5%)

### Phenotypic Clustering

#### Major Clusters

| Cluster | Size | Representative Target | Key Phenotype |
|---------|------|-----------------------|---------------|
| **C1** | 45 | CDK inhibitors | G2/M arrest, ↑DNA content |
| **C2** | 38 | PI3K/mTOR | ↓Cell size, ↓ER |
| **C3** | 32 | EGFR/ErbB | ↓Proliferation |
| **C4** | 28 | JAK | ↓Nuclei, immune phenotype |
| **C5** | 22 | Aurora kinase | Multinucleation |
| **Novel** | 23 | Unknown | Various |

### Target Predictions (Novel Compounds)

| Compound | Predicted Target | Confidence | Reference Match |
|----------|-----------------|------------|-----------------|
| KIN-234 | CDK4/6 | 0.89 | Palbociclib (r=0.85) |
| KIN-089 | BET bromodomain | 0.82 | JQ1 (r=0.79) |
| KIN-456 | DYRK1A | 0.78 | Harmine (r=0.71) |
| KIN-167 | CLK1 | 0.75 | TG-003 (r=0.68) |
| KIN-312 | **Novel MOA** | - | No match |

### Novel MOA Analysis: KIN-312

**Phenotypic Signature:**
```
Feature Category    Effect      Distinctiveness
Mitochondria       Fragmented   Very High
ER                 Expanded     High
Nucleoli           Enlarged     Moderate
Cytoskeleton       Normal       -
Cell shape         Rounded      Moderate
```

**Nearest Reference:** None (max correlation r=0.32)

**Predicted Pathway:** Mitochondrial fission/fusion (novel kinase target)

**Recommendation:** High priority for target deconvolution

### Hit Prioritization

| Rank | Compound | Activity | Selectivity | Novelty | Toxicity | Score |
|------|----------|----------|-------------|---------|----------|-------|
| 1 | **KIN-312** | 8.2 | 9.1 | 9.5 | 8.8 | 8.9 |
| 2 | **KIN-089** | 7.8 | 8.5 | 7.2 | 9.2 | 8.2 |
| 3 | **KIN-456** | 7.5 | 7.8 | 6.8 | 9.0 | 7.8 |
| 4 | **KIN-234** | 8.5 | 7.2 | 4.5 | 8.5 | 7.2 |
| 5 | **KIN-167** | 6.9 | 8.2 | 6.5 | 8.8 | 7.6 |

### Recommended Follow-up

| Priority | Compound | Action | Rationale |
|----------|----------|--------|-----------|
| **High** | KIN-312 | Target deconvolution | Novel MOA |
| **High** | KIN-089 | Biochemical confirmation | BET prediction |
| **Medium** | KIN-456, KIN-167 | Kinase panel screening | Validate targets |
| **Lower** | KIN-234 | Deprioritize | Similar to existing CDK4/6 |

### Structural Analysis

| Compound | Chemotype | Known Kinase Scaffold | SAR Opportunity |
|----------|-----------|----------------------|-----------------|
| KIN-312 | Novel pyrazole | No | High |
| KIN-089 | Triazolopyridine | BET-like | Medium |
| KIN-456 | Benzimidazole | CLK/DYRK | High |
```

### LLM Agent Integration

```python
@tool
def phenotypic_drug_discovery(
    profiles_path: str,
    reference_profiles: str = None,
    prioritization_criteria: dict = None,
    identify_novel: bool = True
) -> str:
    """
    Performs phenotypic drug discovery analysis.

    Args:
        profiles_path: Path to compound profiles
        reference_profiles: Path to annotated references
        prioritization_criteria: Weighting for hit selection
        identify_novel: Flag compounds with novel MOA

    Returns:
        Hit list with MOA predictions and prioritization
    """
    pass
```

---

## References

- **Moffat et al. (2017):** "Opportunities and challenges in phenotypic drug discovery." *Nature Reviews Drug Discovery*
- **Ardigen phenAID Platform](https://ardigen.com/phenotypic-profiling-ardigen-phenaid/)

---

## Author

**MD BABU MIA**
*Artificial Intelligence Group*
*Icahn School of Medicine at Mount Sinai*
md.babu.mia@mssm.edu
